NO20072931L - Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva - Google Patents

Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva

Info

Publication number
NO20072931L
NO20072931L NO20072931A NO20072931A NO20072931L NO 20072931 L NO20072931 L NO 20072931L NO 20072931 A NO20072931 A NO 20072931A NO 20072931 A NO20072931 A NO 20072931A NO 20072931 L NO20072931 L NO 20072931L
Authority
NO
Norway
Prior art keywords
treatment
temozolomide
patient
dosing regimen
cancer based
Prior art date
Application number
NO20072931A
Other languages
English (en)
Inventor
Chen Zong
Benjamin Winograd
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072931(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20072931L publication Critical patent/NO20072931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Det er beskrevet anvendelse av temozolomid til fremstilling av et medikament for behandling av kreft hos en pasient som trenger slik behandling, som omfatter administrering av temozolomid i henhold til forbedrede doseringsregimer og/eller -planer basert på pasientens MGMT-nivå. Det er også beskrevet ytterligere forbedrede doseringsregimer og/eller -planer for behandling av pasienter med temozolomid.
NO20072931A 2004-11-09 2007-06-08 Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva NO20072931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09
PCT/US2005/040449 WO2006052976A2 (en) 2004-11-09 2005-11-07 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level

Publications (1)

Publication Number Publication Date
NO20072931L true NO20072931L (no) 2007-08-03

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072931A NO20072931L (no) 2004-11-09 2007-06-08 Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva

Country Status (13)

Country Link
US (2) US20060100188A1 (no)
EP (1) EP1830845A2 (no)
JP (2) JP2008519584A (no)
CN (1) CN101098696A (no)
AU (1) AU2005304672B2 (no)
BR (1) BRPI0517976A (no)
CA (1) CA2585446A1 (no)
MX (1) MX2007005581A (no)
NO (1) NO20072931L (no)
NZ (1) NZ554831A (no)
TW (1) TW200630089A (no)
WO (1) WO2006052976A2 (no)
ZA (1) ZA200703716B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397440T1 (de) * 2002-02-22 2008-06-15 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
BRPI0517976A (pt) * 2004-11-09 2008-10-21 Schering Corp métodos de tratamento
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
EP2329818A1 (en) * 2006-01-17 2011-06-08 Abbott Laboratories Combination therapy with PARP inhibitors
CL2007000945A1 (es) 2006-04-05 2008-01-25 Schering Corp Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
EP2662374A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
WO2007133496A2 (en) * 2006-05-09 2007-11-22 Schering Corporation Development of a novel assay for mgmt (methyl guanine transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
NZ580982A (en) * 2007-05-08 2012-05-25 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
CA2908353C (en) * 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
MX2021011760A (es) * 2019-03-28 2021-12-10 Univ Jefferson Metodos para el tratamiento de canceres usando antisentido.
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법
CN119318654A (zh) * 2024-12-16 2025-01-17 中国医学科学院基础医学研究所 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
NZ536302A (en) * 1999-03-30 2006-05-26 Schering Corp Cancer treatment regime with temozolomide
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
WO2001085221A2 (en) * 2000-05-12 2001-11-15 Duke University Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
AU2001296511A1 (en) * 2000-09-29 2002-04-08 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
WO2002103013A2 (en) * 2000-10-30 2002-12-27 Gene Logic, Inc. Partially double-stranded nucleic acids, methods of making, and use thereof
ATE502030T1 (de) * 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
BRPI0517976A (pt) * 2004-11-09 2008-10-21 Schering Corp métodos de tratamento
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
US20090247598A1 (en) 2009-10-01
WO2006052976A3 (en) 2006-08-17
US20060100188A1 (en) 2006-05-11
NZ554831A (en) 2009-10-30
ZA200703716B (en) 2008-09-25
WO2006052976A2 (en) 2006-05-18
AU2005304672B2 (en) 2010-03-11
CA2585446A1 (en) 2006-05-18
JP2011121960A (ja) 2011-06-23
JP2008519584A (ja) 2008-06-12
CN101098696A (zh) 2008-01-02
MX2007005581A (es) 2007-05-23
BRPI0517976A (pt) 2008-10-21
TW200630089A (en) 2006-09-01
EP1830845A2 (en) 2007-09-12
AU2005304672A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
LU92692I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BRPI0517976A (pt) métodos de tratamento
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
ATE451340T1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
PL1778209T3 (pl) Sposoby i kompozycje do doustnego dostarczania FTS
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
TW200616606A (en) Treatment and prevention of multi-drug resistance
SE0102887D0 (sv) New formulation
SE0203817D0 (sv) New composition
NO20075508L (no) Stannsoporfinpreparater og administrering
IS8373A (is) Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn
WO2007093519A3 (en) Ibandronate regimen for treating metastatic bone pain
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives
SG146671A1 (en) Therapeutic regimens for administering drug combinations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application